Global Cord Blood Corporation

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Global Cord Blood Corporation (OTC: CORBF) resulting from allegations that Global Cord may have issued materially misleading business information to the investing public.

If you purchased Global Cord securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased Global Cord securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On April 29, 2022, after market hours, Global Cord issued a press release entitled “Global Cord Blood Corporation Announces Entry into Cell Therapy Market by Acquiring Cellenkos and Its Products Rights” which discussed Global Cord’s planned acquisition of Cellenkos, Inc (“CLNK”) (a biotechnology research and development company which utilizes umbilical cord blood (“CB”) as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products and which has agreements with The University of Texas MD Anderson Cancer Center).

On this news, Global Cord’s stock price fell $0.98 per share, or 28%, to close at $2.45 per share on May 2, 2022, the next trading day.

On May 9, 2022, during market hours, Global Cord announced a major investor in many of Global Cord’s Chinese subsidiaries, Blue Ocean Structure Investment Company Limited (“BVI”), “filed in the Grand Court of the Cayman Islands a notice of petition to wind up in respect of the issuer (the ‘Notice of Petition’). Among other things, the Notice of Petition primarily seeks an order that: (1) the issuer refrain from proceeding with a proposed transaction by which the issuer would acquire Cellenkos, Inc., as described in a Form 6-K filed by the Issuer on April 29, 2022 (the ‘Cellenkos Transaction’); (2) the issuer amend and restate its Memorandum and Articles of Association to eliminate the classification of the Board and to add shareholder protective provisions; and (3) the issuer convene an extraordinary general meeting to propose the removal of the current Board and the appointment of alternative directors proposed by [BVI].”

On this news, Global Cord’s stock price fell $0.22 per share, or 8%, to close at $2.41 per share on May 9, 2022.

Follow us on:
Company Name: Global Cord Blood Corporation
Stock Symbol: CORBF
Class Period: N/A
Court: N/A

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top